News Home

Where Will Progenity Inc (PROG) Stock Go Next After It Is Down 22.30% in a Week?

Monday, December 27, 2021 11:07 AM | InvestorsObserver Analysts
Where Will Progenity Inc (PROG) Stock Go Next After It Is Down 22.30% in a Week?

The market has been down on Progenity Inc (PROG) stock recently. PROG gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bearish
Progenity Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on PROG!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With PROG Stock Today?

Progenity Inc (PROG) stock is down -6.5% while the S&P 500 has gained 0.89% as of 11:05 AM on Monday, Dec 27. PROG is down -$0.14 from the previous closing price of $2.23 on volume of 5,221,358 shares. Over the past year the S&P 500 has risen 27.65% while PROG is down -60.93%. PROG lost -$3.73 per share in the over the last 12 months.

More About Progenity Inc

Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products as well as innovating in the field of precision medicine. It utilizes a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics, to molecular testing products and to the development of a suite of investigational ingestible devices and drug and device combinations designed to provide precise diagnostic sampling and drug delivery solutions. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing. The company's operations are carried out in the United States. Click Here to get the full Stock Report for Progenity Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App